%0 Journal Article %A Seyed M. Moghadas %A Thomas N. Vilches %A Kevin Zhang %A Chad R. Wells %A Affan Shoukat %A Burton H. Singer %A Lauren Ancel Meyers %A Kathleen M. Neuzil %A Joanne M. Langley %A Meagan C. Fitzpatrick %A Alison P. Galvani %T The impact of vaccination on COVID-19 outbreaks in the United States %D 2020 %R 10.1101/2020.11.27.20240051 %J medRxiv %P 2020.11.27.20240051 %X Background Global vaccine development efforts have been accelerated in response to the devastating COVID-19 pandemic. We evaluated the impact of a 2-dose COVID-19 vaccination campaign on reducing incidence, hospitalizations, and deaths in the United States (US).Methods We developed an agent-based model of SARS-CoV-2 transmission and parameterized it with US demographics and age-specific COVID-19 outcomes. Healthcare workers and high-risk individuals were prioritized for vaccination, while children under 18 years of age were not vaccinated. We considered a vaccine efficacy of 90% against infection following 2 doses administered 28 days apart achieving 40% vaccine coverage of the overall population. We specified 10% pre-existing population immunity for the base-case scenario and calibrated to an effective reproduction number of 1.5, accounting for current COVID-19 interventions in the US.Results Vaccination reduced the overall attack rate to 1.6% (95% CI: 1.3% - 1.8%) from 7.1% (95% CI: 6.3% - 7.9%) across the same period without vaccination. The highest relative reduction (83-90%) was observed among individuals aged 65 and older. Vaccination markedly reduced adverse outcomes, with non-ICU, ICU hospitalizations, and deaths decreasing by 85.2% (95% CI: 82.3% - 87.6%), 85.3% (95% CI: 82.3% - 87.8%), and 87.8% (95% CI: 85.1% - 90.1%), respectively.Conclusions Our results indicate that vaccination can have a substantial impact on reducing disease transmission and adverse clinical outcomes. However, with uptake of 40% or less in the population, vaccination is unlikely to completely eliminate the need for non-pharmaceutical interventions.Key points Vaccination with 90% vaccine efficacy could substantially mitigate future attack rates, hospitalizations, and deaths, even if only adults are vaccinated. Current non-pharmaceutical interventions remain an important part of outbreak response as vaccines become available and distributed over time.Competing Interest StatementDr. Joanne M. Langley reports that her institution has received funding for research studies from Sanofi Pasteur, GlaxoSmithKline, Merck, Janssen and Pfizer. Dr. Joanne M. Langley also holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. Dr. Neuzil received funding for research studies from Pfizer. Other authors declare no competing interests.Funding StatementCanadian Institutes of Health Research [OV4-170643, COVID-19 Rapid Research]; São Paulo Research Foundation [18/24811-1]; the National Institutes of Health [1RO1AI151176-01; 1K01AI141576-01], and the National Science Foundation [RAPID 2027755; CCF-1918784].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was based on publicly available data and therefore did not require ethics approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe model was implemented in Julia language and is available at: https://github.com/thomasvilches/covid_vac. https://github.com/thomasvilches/covid_vac %U https://www.medrxiv.org/content/medrxiv/early/2020/11/30/2020.11.27.20240051.full.pdf